0000950170-24-088538.txt : 20240731 0000950170-24-088538.hdr.sgml : 20240731 20240731160509 ACCESSION NUMBER: 0000950170-24-088538 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240729 FILED AS OF DATE: 20240731 DATE AS OF CHANGE: 20240731 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ZANTE GREG CENTRAL INDEX KEY: 0001264949 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 241161878 MAIL ADDRESS: STREET 1: C/O SANGAMO BIOSCIENCES, INC STE-A-100 STREET 2: POINT RICHMOND TECH, 501 CANAL BLVD, CITY: RICHMOND STATE: CA ZIP: 94804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 ownership.xml 4 X0508 4 2024-07-29 0001607678 Viking Therapeutics, Inc. VKTX 0001264949 ZANTE GREG C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 false true false false Chief Financial Officer false Common Stock, par value $0.00001 per share 2024-07-29 4 A false 6667 0 A 181521 D Common Stock, par value $0.00001 per share 2024-07-29 4 A false 21667 0 A 203188 D Common Stock, par value $0.00001 per share 2024-07-30 4 S false 12662 56.96 D 190526 D Common Stock, par value $0.00001 per share 2024-07-30 4 S false 2974 57.71 D 187552 D Common Stock, par value $0.00001 per share 2024-07-30 4 S false 500 58.71 D 187052 D The reported securities were subject to a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal. These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.46 to $57.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.46 to $58.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.54 to $58.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. /s/ Michael Morneau as Attorney-in-Fact 2024-07-31